NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma
Status:
Not yet recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The investigators will conduct a prospective, single-arm study to evaluate the safety and
feasibility of neoadjuvant therapy with anti-PD-L1 antibody (SHR-1316, Hengrui Medicine) in
patients with resectable esophageal squamous cell carcinoma (ESCC).